Fresh off a big score at the Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis conference in Amsterdam, the Netherlands, for its oral multiple sclerosis immune modulator BG-12, Biogen Idec has inked a multi-million-dollar deal with privately held Portola Pharmaceuticals Inc. (See BioWorld Today, Oct.